{
  "docId": "019de074-2557-77dc-997c-34813158de99",
  "docSlug": "5df8d2698ec92d4699700c9c99264cb6",
  "documentTitle": "Alkermes | Investor Presentation Deck | 28 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 28,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide outlines the strategic rationale for a corporate spin-off, focusing on the remaining neuroscience-focused entity.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2557-77dc-997c-34813158de99/25",
  "deckHref": "/decks/019de074-2557-77dc-997c-34813158de99",
  "deckJsonHref": "/decks/019de074-2557-77dc-997c-34813158de99.json",
  "deckAnchorHref": "/decks/019de074-2557-77dc-997c-34813158de99#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.81
      },
      "kind": "callout",
      "text": "Separation expected to enhance profitability",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09107eb4-2a35-4804-acbf-6700a0b2e8df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.21
      },
      "kind": "callout",
      "text": "Builds on Alkermes' innovation and excellence in neuroscience",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7624793-fa65-457c-b50c-9130d8fd414f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.28,
        "x": 0.36,
        "y": 0.35
      },
      "kind": "list",
      "text": "Commercial Capabilities: Established commercial capabilities in complex psychiatry and addiction markets; Opportunity to capture further operating leverage",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4963c28e-6755-4865-b3ef-801ce1c67be4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.28,
        "x": 0.06,
        "y": 0.35
      },
      "kind": "list",
      "text": "Proprietary Products: Topline primarily driven by growth of proprietary commercial products in addiction and psychiatry; Complex manufacturing capabilities",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "51400c6a-cbf2-42ab-90ca-bc72d8af053f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.28,
        "x": 0.66,
        "y": 0.35
      },
      "kind": "list",
      "text": "Development Pipeline: Early-stage neuroscience pipeline; ALKS 2680, orexin 2 receptor agonist in phase 1; Portfolio of preclinical neuroscience assets",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5d5a424-b816-4073-b170-f20c3d1c6004",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.05,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "*Assuming separation of the company's oncology business is effected through a spin-off of the oncology business into an independent, publicly-traded company",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c01edb0-2556-4908-adea-658755e9cb9b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "Post-Separation Alkermes* Pure-Play, Commercial-Stage Neuroscience Company",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a4a8c5e4-da87-4aac-9c8b-d0a6f84fc6e0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "3bea4a38-3d15-4975-b328-714d4b2cbbb0",
      "evidence": "Executive Summary",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "breakup-spinoff",
      "slug": null,
      "matchId": "1c198c07-9b7f-42f8-9565-5e2f349f4af3",
      "evidence": "The slide describes the strategic rationale for a corporate spin-off of the oncology business.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 28,
      "from": 13,
      "beatId": "455311ba-8ac4-47bd-a45a-0bcdde58b22a",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The deck outlines clear priorities and a roadmap for growth.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}